iguratimod has been researched along with Kahler Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, Y; Wang, F; Younis, M; Yuan, L; Zhang, L | 1 |
1 other study(ies) available for iguratimod and Kahler Disease
| Article | Year |
|---|---|
Iguratimod-encapsulating PLGA-NPs induce human multiple myeloma cell death via reactive oxygen species and Caspase-dependent signalling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Reactive Oxygen Species; Signal Transduction; Sulfonamides | 2021 |